US5187151A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of binding protein with igf-i as an anabolic growth promoting agent
Assignee: Genentech Inc
•
Filing: 1991-02-12
•
Granted: 1993-02-16
•
Expires: 2011-02-12
Abstract
Abstract A method is disclosed for producing an anabolic state in a mammal by co-administration by subcutaneous injection of a combination of effective amounts of IGF-I and an IGF binding protein in a defined molar ratio in the absence of growth hormone so as to produce a greater anabolic response in the mammal than that achieved using IGF-I alone in an amount equal to that used for IGF-I in the combination. Preferably, the IGF-I is native-sequence, mature human IGF-I, the binding protein is IGFBP-3, and the mammal is human or a non-human animal of economic importance such as a cow or pig.
Inventors
- 👤 Ross G. Clark
- 👤 Venkat R. Mukku
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:00
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4743; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/30
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
70 words
A method for producing an anabolic state in a mammal comprising co-administering to the mammal by subcutaneous bolus injection effective amounts of IGFBP-3 and IGF-I in a molar ratio of IGFBP-3 to IGF-I of about 0.5:1 to about 3:1 so as to produce a greater anabolic state in the mammal than that achieved using an equivalent dose of IGF-I alone, wherein growth hormone is not also administered to the mammal.
Claim 2
Independent Claim
70 words
A method for producing an anabolic state in a mammal comprising co-administering to the mammal by subcutaneous bolus injection effective amounts of IGFBP-3 and IGF-I in a molar ratio of IGFBP-3 to IGF-I of about 0.5:1 to about 3:1 so as to produce a greater anabolic state in the mammal than that achieved using an equivalent dose of IGF-I alone, wherein growth hormone is not also administered to the mammal.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the mammal is an animal.
Claim 4
Dependent Claim
27 words
The method of claim 2 wherein the IGF-I and IGFBP-3 are bovine, ovine, or porcine IGF-I and IGFBP-3, and the animal is bovine, ovine, or porcine, respectively.
Claim 5
Dependent Claim
11 words
The method of claim 1 wherein the mammal is a human.
Claim 6
Dependent Claim
19 words
The method of claim 4 wherein the IGF-I is human native-sequence, mature IGF-I and the IGFBP-3 is human IGFBP-3.
Claim 7
Dependent Claim
20 words
The method of claim 5 wherein the IGF-I is in a sterile, isotonic solution containing a citrate buffer, pH 6.
Claim 8
Dependent Claim
18 words
The method of claim 5 wherein the molar ratio of IGFBP-3 to IGF-I is about 0.8:1 to 1.5:1.
Claim 9
Dependent Claim
28 words
The method of claim 4 wherein the IGF-I is a human native-sequence IGF-I analog having the glutamic acid at position 3 replaced by another amino acid or deleted.
Claim 10
Dependent Claim
10 words
The method of claim 8 wherein the IGF-I is des(1-3)-IGF-I.
Claim 11
Dependent Claim
21 words
The method of claim 9 wherein the des(1-3)-IGF-I is in a sterile, isotonic solution containing acetic acid, pH 3.2 to 4.5.
Claim 12
Dependent Claim
11 words
The method of claim 8 wherein the IGFBP-3 is human IGFBP-3.
Claim 13
Dependent Claim
16 words
The method of claim 1 wherein the effective amount of IGF-I is at least 0.1 mg/kg/day.
Claim 14
Dependent Claim
14 words
The method of claim 4 wherein the effective amount of IGF-I is 1-20 mg/kg/day.
Claim 15
Dependent Claim
34 words
The method of claim 4 wherein the human to be treated has reached a maximum growth level and then a decrease in annualized growth rate after having previously been treated with growth hormone alone.
Claim 16
Dependent Claim
26 words
The method of claim 4 wherein the human to be treated is at an age that is 2-3 years before his or her growth plate closes.
Claim 17
Dependent Claim
25 words
The method of claim 4 wherein the effective amount of IGF-I is less than the dose that gives a maximal growth response using IGF-I alone.
Claim 18
Dependent Claim
15 words
The method of claim 4 wherein the human to be treated is a pregnant woman.
References Cited (Backward Citations)
US5077276A
Cited
EP0294021A1
Cited
WO1989008667A1
Cited
WO1989009268A1
Cited
WO1989009792A1
Cited
WO1990000529A1
Cited
WO1990000569A1
Cited
EP0369943A1
Cited
EP0375438A2
Cited
WO1990006950A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-02-16 | 1996-08-17 | 1997-02-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-02-16 | 2000-08-17 | 2001-02-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-02-16 | 2004-08-17 | 2005-02-16 | $7700.00 | Window Closed / Lapsed |